Mycophenolic Acid (MPA)
MMF is metabolised to mycophenylic acid, which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal or cardiac transplantation when used in combination with ciclosporin and corticosteroids.
Therapeutic drug monitoring for patients undergoing combination immunosuppression therapy following (typically kidney/heart) transplantation.
|Sample & container required||EDTA (lavender top)|
|Sample volume||2 mL (Timed see below)|
|Turnaround time||Within 5 days from receipt of sample into the Leslie Brent Laboratory|
The sample should be taken just before the subsequent dose (trough level) and at a constant interval; 12h;
Test performed 3 times a week;
Not currently performed in house; this is a referred test. Please send specimens directly to the Leslie Brent Laboratory, West London Renal and Transplant Centre, Hammersmith Hospital 020 331 36637 Clinical Biochemistry will forward any specimens received to the Leslie Brent Laboratory.